vimarsana.com
Home
Live Updates
IntelGenx Announces First Parkinsons Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 MONTPARK Clinical Trial -April 08, 2024 at 07:45 am EDT : vimarsana.com
IntelGenx Announces First Parkinson's Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 'MONTPARK' Clinical Trial -April 08, 2024 at 07:45 am EDT
SAINT LAURENT, Quebec, April 08, 2024 -- IntelGenx Corp. today announced that Montelukast VersaFilm® has been administered to the first Parkinson’s Disease patients in the Phase 2 clinical...
Related Keywords
Sweden ,
Quebec ,
Canada ,
United States ,
Saint Laurent ,
Canadian ,
Swedish ,
Dwight Gorham ,
Stephen Kilmer ,
Andre Godin ,
Montelukast Versafilm ,
Exchange Commission ,
Intelgenx Corp ,
Drug Administration ,
Swedish University ,
Intelgenx Technologies Corp ,
World Health Organization ,
Parkinson Foundation ,
Securities Exchange ,
Karolinska University Hospital ,
Company Or Intelgenx ,
Per Svenningsson ,
Lead Principal ,
Health Organization ,
Leukotriene Receptor Antagonist Montelukast ,
Looking Information ,
Securities Exchange Act ,
Securities Act ,
United States Securities ,
Intelgenx Technologies ,
Markets ,
vimarsana.com © 2020. All Rights Reserved.